FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin “Pay-for-Delay” Case The Federal Trade Commission has filed an amicus brief in the U.S. Court of Appeals for the Second Circuit, recommending that it hold a rehearing before all the judges (“en banc”) of the Ciprofloxacin (Cipro) “pay-for-delay” case. The case concerns payments made by […]
Tag Archives: pay for delay Health Care Prescription Drugs Competition
Statement by FTC Chairman Jon Leibowitz Regarding Todays Decision by the U.S. Court of Appeals for the Second Circuit in the Ciprofloxacin “Pay-for-Delay” Case
Federal Trade Commission Chairman Jon Leibowitz issued the following statement regarding today’s decision by the U.S. Court of Appeals for the Second Circuit, which invited the plaintiffs in the Ciprofloxacin drug patent settlement case to seek further review by the full court of appeals because of the “exceptional importance” of the antitrust implications of pay-for-delay […]
Statement by FTC Chairman Jon Leibowitz Regarding Today’s District Court Decision Denying a Motion to Dismiss the Commission’s Pay-For-Delay Case Against Cephalon Inc.
Today’s decision seems to reflect a growing understanding—first in Congress now in the courts—that brand name drug companies must not be allowed to make pay-offs to their generic competitors to keep low-cost generic drugs off the market. These deals are costing American consumers $3.5 billion a year in higher drug costs. Related posts: FTC Files […]
Statement by FTC Chairman Jon Leibowitz Regarding Continuing Need for Legislation Banning Illegal Pay-for-Delay Drug Settlements
The Federal Trade Commission will continue working on behalf of Americans who are struggling to pay for their health care. According to our economic estimates, consumers would pocket about $3.5 billion a year if these unconscionable deals were stopped and they had earlier access to generic drugs. It’s not a question of whether this should […]
Statement of Federal Trade Commission Chairman Jon Leibowitz on Ending Pay-for-Delay Drug Settlements, Praises Inclusion in Presidents Health Care Proposal
“When drug companies agree not to compete, consumers lose,” said Federal Trade Commission Chairman Jon Leibowitz. “Ending pay-for-delay settlements will help control drug costs. We’re delighted about the President’s resolute support for this bipartisan initiative.” (JDL stmt) Related posts: Statement by FTC Chairman Jon Leibowitz Regarding Today’s District Court Decision Denying a Motion to Dismiss […]
FTC Chairman, Members of Congress Call for Legislation to End Sweetheart Pay-for-Delay Deals That Keep Generic Drugs Off the Market
Federal Trade Commission Chairman Jon Leibowitz and key members of Congress, including Representative Chris Van Hollen, Chairman Bobby Rush, and Representative Mary Jo Kilroy, today renewed their call for legislation that would put an end to anticompetitive patent settlements, which drug manufacturers have been using to keep less-expensive medicines off the market and charge consumers […]
Statement by FTC Chairman Jon Leibowitz on Adoption of the Pay for Delay Amendment to the Americas Affordable Health Choices Act of 2009 by the House Energy and Commerce Committee
I commend the House Energy and Commerce Committee for adopting the Protecting Consumer Access to Generic Drugs Act (H.R.1706) as an amendment to the omnibus health reform legislation. If enacted into law, this measure will put an end to the sweetheart deals between brand and generic pharmaceutical companies that force consumers to wait –sometimes years– […]
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
In a speech today before the Center for American Progress in Washington, D.C., Federal Trade Commission Chairman Jon Leibowitz said that an internal FTC analysis projects that stopping collusive “pay-for-delay” settlements between brand and generic pharmaceutical firms would save consumers $3.5 billion a year and also reap significant savings for the federal government, which pays […]
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
Testifying today on behalf of the Federal Trade Commission before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition Policy, Bureau of Competition Director Richard A. Feinstein said that anticompetitive patent settlements in the U.S. pharmaceutical industry delay consumer access to lower-cost generic drugs, and impose “enormous costs” on consumers; employers; federal, state and […]
FTC Sues Drug Companies for Unlawfully Conspiring to Delay the Sale of Generic AndroGel Until 2015
The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. “At a time […]